Market Research Report
Anal Cancer - Pipeline Review, H1 2020
|Published by||Global Markets Direct||Product code||213060|
|Published||Content info||525 Pages
Delivery time: 1-2 business days
|Anal Cancer - Pipeline Review, H1 2020|
|Published: February 28, 2020||Content info: 525 Pages||
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Anal Cancer - Pipeline Review, H1 2020, provides an overview of the Anal Cancer (Oncology) pipeline landscape.
Anal cancer starts in the anus. Symptoms include rectal bleeding, rectal itching, a lump or mass at the anal opening, pain or a feeling of fullness in the anal area, narrowing of stool, pain or a feeling of fullness in the anal area. Predisposing factors include HPV infections, smoking and lowered immunity.
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Anal Cancer - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Anal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Anal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Anal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 20, 16, 1 and 5 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.
Anal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.